Viatris Inc. stock rises Friday, outperforms market
Viatris Inc. (VTRS) stock advanced 1.90% on Friday, closing at $16.65, and outperforming the broader market. The S&P 500 Index rose 0.37% and the Dow Jones Industrial Average rose 0.58% during the same trading session. Viatris Inc. is currently trading 5.02% below its 52-week high of $17.53, which was set on May 14th.
FDA accepts Viatris' NDA for fast-acting non-opioid pain therapy
The FDA has accepted Viatris' New Drug Application (NDA) for its non-opioid pain therapy, ANX-005. This drug is intended for acute pain and has received Fast Track designation. The acceptance indicates progress for Viatris in addressing the need for non-addictive pain management solutions.
What Viatris (VTRS)'s Fast-Acting Pain Drug Filing and Profit Uptick Means For Shareholders
Viatris Inc. reported an uptick in Q1 revenue and net income and received FDA acceptance for review of its fast-acting meloxicam drug (MR-107A-02) for acute pain. This move signifies Viatris's strategy to shift towards higher-value, differentiated medicines from its traditional generic base. The article explores how these developments might impact the company's investment narrative and future financial performance, with analysts projecting varied outcomes for revenue and earnings by 2029.
What Viatris (VTRS)'s Fast-Acting Pain Drug Filing and Profit Uptick Means For Shareholders
Viatris Inc. reported an uptick in Q1 profit and the FDA accepted for review its New Drug Application for a fast-acting meloxicam formulation for acute pain. This filing, coupled with improving quarterly profitability, signals a strategic shift for Viatris towards higher-value, differentiated medicines. Shareholders will be watching to see if the company can maintain consistent execution against its 2026 guidance and continue to improve its earnings quality.
How Strong Q1 Earnings and Executive Departures At Collegium Pharmaceutical (COLL) Have Changed Its Investment Story
Collegium Pharmaceutical reported strong Q1 2026 net income and reaffirmed its full-year product revenue guidance, signaling continued commercial momentum. However, upcoming departures of its Chief Commercial Officer and Chief Medical Officer introduce potential execution risks. The article examines how these events impact Collegium's investment narrative, particularly concerning its pain and ADHD drug portfolio and upcoming patent expirations.
Lilly, AbbVie, J&J, AZ lead an uptick in Big Pharma Q1 growth, with Novo again bringing up the rear
The first quarter of this year saw an uptick in biopharma sales, with eight of the top-25 companies achieving double-digit year-over-year growth, compared to six in each quarter of 2025. Eli Lilly led the growth with a 56% increase, extending its reign as the top performer for six consecutive quarters. Other significant contributors to this growth included Regeneron, AstraZeneca, AbbVie, Sandoz, Johnson & Johnson, Astellas, and Daiichi Sankyo, while Novo Nordisk experienced the largest sales decline for the second consecutive quarter.
Viatris Inc. stock rises Wednesday, outperforms market
Viatris Inc. (VTRS) stock increased by 2.60% on Wednesday, closing at $16.59. This performance outpaced the broader market, with both the S&P 500 Index and the Dow Jones Industrial Average also seeing gains. Despite the rise, Viatris Inc. finished 5.36% below its 52-week high.
Viatris (VTRS): Buy, Sell, or Hold Post Q1 Earnings?
Despite a recent 58.2% surge in stock price, analysts are cautious about Viatris (VTRS) post-Q1 earnings. The company's long-term revenue growth (1.1% annualized) and EPS decline (9.2% annually) over the past five years are cited as concerns. Additionally, a negative five-year average Return on Invested Capital (-2.4%) suggests inefficient growth initiatives, leading to a recommendation to avoid the stock for now.
Viatris (VTRS): Buy, Sell, or Hold Post Q1 Earnings?
Despite a recent 58.2% surge in stock price fueled by solid Q1 earnings, analysts warn against Viatris (VTRS) due to disappointing long-term revenue growth, declining earnings per share (EPS), and negative return on invested capital (ROIC). The stock is currently trading at $16.13 per share, with experts recommending investors avoid it for now, suggesting better opportunities exist elsewhere. The article highlights concerns about the company's profitability and capital efficiency, advising caution despite its recent market momentum.
Barclays Adjusts Price Target on Viatris to $22 From $17, Maintains Overweight Rating
Barclays has increased its price target for Viatris (VTRS) shares to $22 from $17, while reiterating an Overweight rating on the stock. This adjustment suggests a positive outlook from the firm regarding Viatris's future performance.
Viatris Inc. stock falls Tuesday, underperforms market
Viatris Inc. (VTRS) stock fell 2.00% on Tuesday, closing at $16.17, underperforming the broader market. The S&P 500 Index and Dow Jones Industrial Average also experienced declines. Viatris Inc. is currently trading 7.76% below its 52-week high.
FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy
Viatris announced that the FDA has accepted its New Drug Application (NDA) for MR-107A-02, a fast-acting meloxicam formulation intended as a non-opioid treatment for moderate-to-severe acute pain. A decision is expected by December 27, 2026, positioning the drug as a potential first-line option based on positive Phase III trial data showing rapid onset, durable relief, and reduced opioid use. The NDA is supported by studies in patients recovering from herniorrhaphy or bunionectomy surgeries, demonstrating the therapy's efficacy and safety in achieving primary and secondary endpoints.
FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy
Viatris (VTRS) announced that the FDA has accepted its New Drug Application (NDA) for MR-107A-02, a fast-acting meloxicam formulation intended as a non-opioid treatment for moderate-to-severe acute pain. The FDA's decision is anticipated on December 27, 2026, marking a significant step for this potential first-line treatment. The NDA is supported by positive Phase III data showing rapid pain relief, reduced opioid use, and a well-established safety profile, with the candidate achieving primary and secondary endpoints in trials.
Takeda cuts send layoffs soaring in May, rising year over year
BioPharma layoffs are significantly increasing in May 2026, primarily driven by Takeda's announcement of 4,500 job cuts. While fewer companies are reporting layoffs compared to the previous year, the number of affected employees is rising, with a 24% increase in total layoffs from January 1 to May 15, 2026, compared to the same period in 2025. This trend indicates deeper cuts from fewer companies, with other major layoffs announced by BioNTech and Viatris also contributing to the surge.
U.S. FDA accepts Viatris new drug application for fast-acting meloxicam for the treatment of moderate-to-severe acute pain
The U.S. FDA has accepted Viatris's new drug application (NDA) for a fast-acting meloxicam intended for the treatment of moderate-to-severe acute pain. This development follows Viatris's presentation at the Bank of America Global Healthcare Conference and recent adjustments to its price target by analysts. The company also reported strong Q1 2026 earnings, beating estimates with increased adjusted EPS and revenue.
FDA accepts Viatris application for fast-acting meloxicam
The FDA has accepted Viatris Inc.'s New Drug Application for MR-107A-02, a fast-acting meloxicam formulation for moderate-to-severe acute pain. This non-opioid treatment has a Prescription Drug User Fee Act goal date of December 27, 2026, and is supported by positive Phase 3 trial data. Viatris recently reported strong Q1 2026 financial results, exceeding analyst expectations for both EPS and revenue.
Turbo Energy grows revenue 107% as it shifts into AI-run power infrastructure
Turbo Energy (Nasdaq:TURB) reported a 107% year-over-year revenue growth in FY2025, reaching $23.46 million, and significantly narrowed its operating and net losses. The company is strategically transitioning towards an AI-driven intelligent energy infrastructure model, focusing on industrial, defense, and international projects. Early 2026 capital raises also increased shareholders' equity, strengthening its financial position for continued expansion.
U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain
Viatris Inc. announced that the U.S. FDA has accepted its New Drug Application for fast-acting meloxicam (MR-107A-02), a non-opioid treatment for moderate-to-severe acute pain, setting a PDUFA goal date of December 27, 2026. This acceptance is a significant step towards providing an alternative to opioids for the more than 80 million individuals in the U.S. who experience acute pain annually. The application is supported by positive data from two Phase 3 clinical trials, which demonstrated rapid onset, strong and sustained pain relief, and a significant reduction in opioid usage, with a safety profile consistent with known meloxicam properties.
Viatris Inc. (VTRS) Stock Analysis: Exploring a 6.19% Potential Upside in the Healthcare Sector
This article provides an analysis of Viatris Inc. (VTRS) stock, highlighting its strong market presence in the healthcare sector with a diverse portfolio of generic and specialized drugs. Despite facing profitability challenges with negative EPS and ROE, the company shows a potential upside of 6.19% based on its Forward P/E ratio and target price. Viatris also boasts commendable revenue growth, healthy free cash flow, and strategic collaborations, making it a stock worth watching for investors.
Amphastar Pharmaceuticals Q1 2026: Revenue Miss and Pricing Pressures on BAQSIMI
Amphastar Pharmaceuticals reported flat revenue and missed adjusted profit forecasts in Q1 2026, causing a negative stock response. The company attributed these results to persistent price reductions, particularly for its diabetes treatment BAQSIMI, and increased competition. Analysts inquired about BAQSIMI's pricing challenges, timelines for synthetic corticotropin, insulin aspart biosimilar initiatives, and the market potential for new products, alongside concerns about future glucagon sales.
Viatris Shareholders Approve Directors, Pay and Auditor
Viatris Inc. shareholders approved the election of thirteen director nominees, executive compensation for 2025 on a non-binding advisory basis, and ratified Deloitte & Touche LLP as the independent registered public accounting firm for fiscal 2026 at their annual meeting on May 15, 2026. This signals continuity in governance and investor support for the company's practices. Analysts currently rate VTRS as a Hold with an $18.00 price target, and TipRanks' AI Analyst views it as Neutral, noting mixed financial fundamentals and supportive but overextended technicals.
Viatris Shareholders Approve Directors, Pay and Auditor
Viatris Inc. held its 2026 annual meeting where shareholders approved the election of thirteen director nominees, the 2025 compensation for named executive officers on a non-binding advisory basis, and ratified Deloitte & Touche LLP as the independent registered public accounting firm for fiscal 2026. This signals continuity in governance, support for executive pay practices, and stability in financial reporting for the global healthcare company.
Elanco Animal Health (NYSE:ELAN) - Stock Analysis
Elanco Animal Health (NYSE:ELAN) is currently trading at US$19.86, which is 45.8% below its estimated fair value of US$28.77. Analysts expect Elanco's earnings to grow by 55.82% per year. The company recently exceeded Q1 2026 forecasts, showing strong product growth in both pet and farm animals, and raised its full-year 2026 guidance.
Viatris Inc (VTRS) Stock Down 4.5% but Still Overvalued -- GF Sc
Viatris Inc (VTRS) shares recently dropped by 4.5% to $16.52, yet GuruFocus assesses the stock as "Significantly Overvalued" with a GF Value™ of $11.00. Despite a 96.7% year-over-year growth, its GF Score™ of 61/100 reveals weaknesses in financial strength and growth, further compounded by insiders selling $0.3 million in shares without any buying activity. Investors are advised to exercise caution due to the overvaluation and weak insider confidence.
Viatris Shareholders Approve Directors, Pay and Auditor
Viatris Inc. shareholders approved key proposals at their 2026 annual meeting on May 15, electing thirteen director nominees, endorsing the 2025 executive compensation, and re-ratifying Deloitte & Touche LLP as the independent auditor for fiscal 2026. This reflects continuity in governance and financial oversight, with the company (VTRS) currently holding a "Hold" rating from analysts and a "Neutral" outlook from TipRanks' AI Analyst.
Viatris (VTRS) investors elect full board and approve 2025 pay, auditor
Viatris Inc. shareholders elected all thirteen director nominees, approved the 2025 executive compensation on a non-binding advisory basis, and ratified Deloitte & Touche LLP as the independent auditor for the fiscal year ending December 31, 2026, during their 2026 annual meeting. Each proposal received a majority of votes in favor, demonstrating shareholder confidence in the company's governance and compensation practices.
Viatris Inc. stock falls Friday, underperforms market
Viatris Inc. (VTRS) stock fell 4.52% on Friday, closing at $16.48. This decline occurred during a broader market downturn, with both the S&P 500 Index and Dow Jones Industrial Average also recording losses. This marks the second consecutive day of losses for Viatris.
Ionis Pharmaceuticals, Inc. - Common Stock (NQ: IONS
This article provides recent news headlines related to Ionis Pharmaceuticals (IONS), primarily from April 2021. Topics include market movements such as stocks hitting 52-week lows, biotech pulse updates, and specific company news like Ionis's distribution agreement expansion and Akcea workforce restructuring. The current stock price for Ionis is also listed.
Viatris Inc. - Common Stock (NQ: VTRS
This page provides a collection of recent news headlines related to Viatris Inc. (Nasdaq: VTRS). The articles cover various topics including class action lawsuits against the company, its Q1 earnings report revealing positive data for two drugs, revised full-year profit outlook, and discussions around market performance of S&P500 stocks. Several alerts from law firms about securities fraud class action lawsuits targeting Viatris are also prominent.
Naloxone Market to See Booming Growth 2026-2033 | EMERGENT, Indivior PLC, Akorn, Inc
The naloxone market is projected to reach USD 3,370.5 Mn by 2033, growing at a CAGR of 10.8% from USD 1,644.1 Mn in 2026. A new report by Coherent Market Insights provides in-depth analysis of the market dynamics, competitive landscape, and growth opportunities, segmenting it by strength, route of administration, and distribution channel. Key players like EMERGENT, Indivior PLC, and Akorn, Inc. are highlighted, along with regional market insights and forecasts.
5 Revealing Analyst Questions From Viatris’s Q1 Earnings Call
Viatris exceeded Wall Street's expectations in Q1, driven by strong commercial execution, especially in Greater China, and new product contributions. Management reiterated full-year guidance despite the strong quarter, focusing on ongoing initiatives. Analyst questions revealed insights into China's growth durability, R&D study designs, commercial strategies for new products, business development priorities, and the balance of R&D investments.
Viatris Inc. stock rises Wednesday, outperforms market
Viatris Inc. (VTRS) stock increased by 1.16% on Wednesday, closing at $17.37. This performance outpaced the broader market, as the S&P 500 Index rose 0.58%, while the Dow Jones Industrial Average experienced a slight decline of 0.14%. This marks the second consecutive day of gains for Viatris.
Viatris Hypertension Drug Doesn’t Copy J&J Patents, Court Says
An appeals court has ruled that Viatris Inc.'s generic version of Johnson & Johnson's hypertension drug Veletri does not infringe on two patents held by J&J unit Actelion Pharmaceuticals Ltd. The court determined that Viatris's drug falls outside the pH range specified in the patents, affirming a lower court's decision. This ruling means Viatris can proceed with its generic product without patent infringement issues.
Viatris Hypertension Drug Doesn’t Copy J&J Patents, Court Says
An appeals court has ruled that Viatris Inc.'s generic version of Johnson & Johnson unit Actelion Pharmaceuticals Ltd.'s hypertension drug Veletri does not infringe on two of J&J's patents. The court found that Viatris's proposed drug falls outside the pH range specified in the patents, affirming a lower court's decision. This ruling allows Viatris to proceed with its generic version of the drug.
Viatris Hypertension Drug Doesn’t Copy J&J Patents, Court Says
An appeals court has ruled that Viatris Inc.'s generic version of Johnson & Johnson unit Actelion Pharmaceuticals Ltd.'s hypertension drug Veletri does not infringe on two of J&J's patents. The court affirmed that Viatris's drug falls below the specific pH range mentioned in the patents, using evidence that pH measurement should be taken at standard temperature. This decision supports the US District Court for the Northern District of West Virginia's initial finding.
Viatris Hypertension Drug Doesn’t Copy J&J Patents, Court Says
Viatris Inc. has successfully argued in an appeals court that its generic version of Johnson & Johnson's hypertension drug Veletri does not infringe on two of J&J's patents. The US Court of Appeals for the Federal Circuit ruled that Viatris's drug falls outside the specified pH range in J&J's patents, upholding a previous decision by the US District Court for the Northern District of West Virginia. This decision allows Viatris to market its generic hypertension drug without patent infringement claims from J&J.
Viatris (VTRS) Is Up 10.6% After Q1 Beat, CFO Change And Outlook Reaffirmation - What's Changed
Viatris (VTRS) recently reported strong first-quarter 2026 results, with increased revenue and positive net income, and reaffirmed its full-year revenue guidance. The company also announced a change in its CFO, with Paul Campbell stepping in as interim CFO following Theodora Mistras's departure. This financial performance and governance shift are key factors influencing Viatris's investment narrative, emphasizing disciplined cost management and execution against guidance amidst ongoing market pressures.
Viatris Inc. stock rises Tuesday, outperforms market
Viatris Inc. (VTRS) saw its stock rise by 1.48% on Tuesday, closing at $17.17. This increase occurred during a mixed trading session, where the Dow Jones Industrial Average gained 0.11% but the S&P 500 Index fell 0.16%. The positive performance broke a two-day losing streak for the company's stock.
GM1 Gangliosidosis Treatment Market to Reach USD 626.86 Million
The global GM1 Gangliosidosis Treatment Market is projected to reach USD 626.86 million by 2033, growing at a CAGR of 16.6% from 2026. North America currently leads the market with a 40.0% share, driven by strong research infrastructure and gene therapy adoption. Key players like Passage Bio, Lysogene, and Sanofi are contributing to market growth through advancements in gene replacement therapies and increasing investment in rare disease research.
Heron Therapeutics (NasdaqCM:HRTX) Stock Forecast & Analyst Predictions
Heron Therapeutics is forecast to grow earnings by 58.9% and revenue by 13.9% per annum, though analysts no longer expect the company to break even in the foreseeable future, predicting a net loss of US$39.7m in 2028. Recent Q1 2026 earnings missed analyst expectations, and the company's share price has shown volatility, dropping 35% over the past year. Analysts have also reduced price targets to an average of US$4.33, indicating caution despite the potential for future upside from revised profit outlook and discount rates.
Viatris Inc. stock falls Monday, underperforms market
Viatris Inc. (VTRS) experienced a 1.46% decline in its stock price on Monday, closing at $16.92. This performance put it behind the broader market, as both the S&P 500 Index and the Dow Jones Industrial Average saw gains of 0.19% on the same day. This marked the second consecutive day of losses for Viatris.
UBS Adjusts Viatris Price Target to $23 From $20
UBS has increased its price target for Viatris (VTRS) to $23 from $20, while maintaining a Buy rating on the stock. This adjustment is based on a discounted cash flow (DCF) model and factors in Viatris's recent financial disclosures and business outlook. The firm notes Viatris's potential for multiple expansion with upcoming catalysts.
UBS Adjusts Viatris Price Target to $23 From $20
UBS has increased its price target for Viatris Inc. (NASDAQ: VTRS) to $23 from the previous $20. This adjustment comes after Viatris reported its Q1 2026 earnings, which saw revenues and adjusted earnings rise, outperforming analyst estimates. The company has also reaffirmed its earnings guidance for the fiscal year 2026.
A Look At Collegium Pharmaceutical (COLL) Valuation As Earnings Jump And AZSTARYS Acquisition Is Proposed
Collegium Pharmaceutical (COLL) recently reported strong first-quarter 2026 earnings, showing increased profitability and progress in ADHD and pain product lines, complemented by a proposed AZSTARYS acquisition. Despite positive long-term shareholder returns, its recent share performance has been mixed. The company is considered undervalued by analysis, with a fair value around $54.17 compared to its current price of $37.80, driven by anticipated margin expansion and disciplined capital use.
Viatris Announces Second Quarter 2024 Dividend
Viatris Inc. has announced its second-quarter 2024 dividend. This news was delivered by Quantisnow, a platform that provides real-time market data and news for investors. The article also lists recent analyst ratings for Viatris (VTRS) and links to related press releases and SEC filings concerning the company.
Research Alert: CFRA Keeps Hold Opinion On Shares Of Viatris Inc.
CFRA has maintained its Hold opinion on shares of Viatris Inc. This research alert indicates no change in CFRA's investment stance regarding the company's stock.
Viatris Inc. stock falls Friday, underperforms market
Viatris Inc. (VTRS) stock declined 1.27% on Friday, closing at $17.17, despite an overall positive trading day for the broader market. The S&P 500 Index and Dow Jones Industrial Average both saw gains, indicating that Viatris underperformed its benchmarks. This fall ended a five-day winning streak for the company's stock.
Viatris Inc. Stock 12‑Month Price Target Raised to $17.25, Implies 1% Downside
Viatris Inc.'s 12-month stock price target has been raised from $17 to $17.25 by 8 analysts, with individual forecasts ranging from $12 to $20 per share. Based on the May 7 closing price, this updated target suggests a potential downside of approximately 1%. The consensus among 13 covering analysts remains a "Buy" rating.
Viatris Earnings: Stable Base Business and Pipeline Progression Mark a Solid Start to 2026
Viatris reported strong first-quarter 2026 results, exceeding FactSet consensus with 8% revenue growth and 17% adjusted EPS growth. The company maintained its full-year guidance of 3% revenue growth and 2% EPS growth. Following the positive earnings report, Viatris's shares traded up by approximately 5% in intraday trading.
Collegium Pharmaceutical (COLL) Earnings Growth Far Outpaces Revenue And Tests Cautious Narratives
Collegium Pharmaceutical (COLL) reported impressive Q1 2026 results, with earnings growth significantly outpacing revenue, indicating improved profitability. Despite concerns over revenue growth being below the wider US market and a notable one-off loss, the company's P/E ratio is near the industry average, yet a Discounted Cash Flow (DCF) fair value suggests significant undervaluation. This performance challenges some cautious narratives, presenting a mixed picture of risk and reward for investors.
